cas 61079-72-9|| where to buy 2,3,4-Trifluorobenzoic acid

製品名:2,3,4-Trifluorobenzoic acid

IUPAC Name:2,3,4-trifluorobenzoic acid

包装単位	有効在庫	価格（USD）
CM158647-500g	in stock	ǊĽĽ
CM158647-1000g	in stock	ȎƄȎ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 61079-72-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:61079-72-9; 分子式:C7H3F3O2; 融点:-; SMILESコード:O=C(O)C1=CC=C(F)C(F)=C1F; 密度:

: カタログ番号:CM158647; 分子量:176.09; 沸点:245.259°C at 760 mmHg; MDL番号:MFCD00061232; 保管方法:Store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Encorafenib plus Binimetinib; U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

: Mirdametinib; SpringWorks Therapeutics announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The NDA submission includes data from the Phase 2b ReNeu trial. The primary endpoint was confirmed objective response rate (ORR). The BICR-confirmed objective response rate was 52% in pediatric patients and 41% in adult patients. Mirdametinib treatment showed deep and durable responses and demonstrated significant improvements in key secondary patient-reported outcome measures.